Stream Biomedical nominated for 2026 Prix Galien USA Best Startup award

Stream Biomedical has been nominated for the 2026 Prix Galien USA Award for Best Startup, bringing national attention to its rLG3 program for neurological diseases. Winners will be announced Oct. 29 in New York City at the American Museum of Natural History.

Why it matters: - The nomination puts Stream Biomedical’s rLG3 program in the spotlight as a potential new approach for diseases with few effective treatment options. - rLG3 is designed to amplify an endogenous repair pathway tied to the brain’s recovery after injury or disease. - Stream is initially targeting Alzheimer’s disease, with possible broader use in other neurological disorders marked by neurovascular dysfunction.

What happened: - The Galien Foundation named Stream Biomedical a nominee for the 2026 Prix Galien USA Award for Best Startup. - The announcement came Aug. 13, 2026. - Winners will be honored Oct. 29, 2026, at the American Museum of Natural History in New York City. - The award program also includes nominees in Best Digital Health Solution, Best Medical Technology, and Incubators, Accelerators and Equity.

The details: - Stream Biomedical is a Houston-based biotechnology company developing regenerative biologic therapies for neurological diseases. - The nomination recognizes the company’s discovery and development of rLG3, described as a first-in-class recombinant protein therapeutic. - rLG3 is the 21-kDa recombinant analog of the LG3 domain of Perlecan Domain V. - Stream licensed Perlecan Domain V technology from Texas A&M University. - The company says its science is built on three linked advances: identifying an endogenous repair pathway, developing rLG3 to amplify that pathway, and creating a development strategy that uses advanced imaging and molecular biomarkers to measure biological activity and target engagement. - Preclinical studies showed rLG3 reduced blood-vessel leakage and inflammation, protected brain tissue and improved recovery in models of Alzheimer’s disease, traumatic brain injury, ischemic stroke, spinal cord injury and diabetes-related vascular disease. - Stream has successfully manufactured highly purified rLG3 to support its planned clinical development program. - Research supporting the discovery and preclinical development of rLG3 has been supported in part by National Institutes of Health grants. - Stream’s scientific and operational team includes CEO William Schwieterman, Chief Scientific Officer H. Davis Adkisson, Director of Translational Programs Bryan Clossen, and Director of Manufacturing & CMC Seth Fisher. - The company’s Scientific Advisory Board includes Lennart Mucke, Ramon Diaz-Arrastia and Andy Shih. - Stream’s clinical focus is Alzheimer’s disease, with future applications in other neurological disorders. - More information is available in the company’s announcement. - Related research is available in the cited journal article. - Stream also shared a LinkedIn company page.

Between the lines: - The Prix Galien nomination signals external validation for Stream’s platform at a time when neuroscience drug development has produced limited breakthroughs. - The company is positioning rLG3 not just as a single-disease candidate, but as a platform therapy for neurovascular dysfunction. - The biomarker-driven development plan suggests Stream is trying to de-risk clinical testing by measuring whether the drug hits its biological target earlier in development.

What's next: - The next clear milestone is the Prix Galien USA ceremony on Oct. 29, 2026. - Stream will continue clinical development of rLG3 for Alzheimer’s disease and could expand into other neurological indications if early results support the platform approach. - The company’s near-term focus is translating preclinical findings into human data that can show safety, target engagement and clinical benefit.